A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naive Subjects With Chronic HCV Infection
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Sofosbuvir (Primary) ; Velpatasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 10 Nov 2015 Results published in the Annals of Internal Medicine
- 21 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Apr 2014 Results will be presented at the 49th Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress 2014) according to a Gilead Sciences media release. Results were also summarised in the media release.